Acrivon Therapeutics, Inc. (ACRV) 股票分析

公司概述

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to discovering and developing oncology medicines for patients whose tumors are predicted to be sensitive to specific therapeutic agents through the utilization of its generative phosphoproteomics platform. The enterprise functions within the Healthcare sector, specifically targeting the Biotechnology industry, where it focuses on translating predictive oncology models into precise treatment options for solid tumors. Currently, the company employs a workforce of 74 individuals and maintains a total market capitalization of $60.05 million. Given that the company reports N/A for annual revenue, these financial metrics indicate that Acrivon is a pre-revenue entity typical of early-stage biotechnology firms, where significant capital is allocated toward research and development rather than commercial sales, reflecting a strategic position focused on product discovery rather than current market share or income generation.

财务健康

The company reports N/A for revenue and a net income loss of $-77,905,000 over the trailing twelve months, while EBITDA stands at $-82,758,000, revealing a cost structure dominated by heavy operational expenditures and research investments with no offsetting sales revenue to generate gross profit. Free cash flow is recorded at $-39,543,248, which signifies a substantial cash outflow necessary to fund ongoing clinical trials and platform development, thereby constraining immediate financial flexibility until commercial products are launched. All three margin metrics—gross margin, operating margin, and profit margin—are reported as 0.0%, a standard characteristic for clinical-stage companies lacking revenue streams, indicating that the business model has not yet transitioned from burn to break-even or profitability. The balance sheet holds $118.58 million in cash against $2.71 million in debt, resulting in a debt-to-equity ratio of 2.41, which suggests a highly leveraged position relative to equity but mitigated by a robust cash reserve that exceeds total liabilities by a wide margin. Liquidity is further supported by a current ratio of 7.69, demonstrating an exceptionally strong ability to meet short-term obligations with current assets. However, the return on equity stands at -53.9% and return on assets at -32.2%, metrics that reflect the negative impact of substantial losses on shareholder value and asset efficiency, common for biotech firms in the developmental phase before reaching commercial viability.

估值评估

Valuation multiples for Acrivon present a complex picture, with a trailing P/E ratio listed as N/A due to the absence of positive net income, while the forward P/E is calculated at -0.83, implying that future earnings expectations remain deeply negative or that the market is pricing in significant time horizons before profitability. The price-to-book ratio is 0.44, suggesting that the market values the company at less than half of its net asset book value, which may reflect skepticism regarding the commercialization potential of its pipeline or the high risk associated with its clinical-stage assets. Alternative valuation metrics such as price-to-sales (N/A) and EV/EBITDA (0.67) are utilized, where the low EV/EBITDA of 0.67 typically indicates a distressed or deep-value scenario, although for a biotech firm, it primarily highlights the lack of current earnings power rather than undervaluation in the traditional sense. The stock has traded between a 52-week low of $1.05 and a 52-week high of $3.56, and without the specific current share price provided in the data, the relative positioning within this volatility range cannot be precisely calculated, though the range itself demonstrates significant price discovery activity. The beta value is 1.74, indicating that the stock exhibits price volatility that is more than double that of the broader market, exposing investors to heightened risk during periods of market turbulence or sector-specific shifts.

Growth & Income

Growth metrics for the company are reported as N/A for both revenue growth year-over-year and earnings growth year-over-year, as the absence of positive revenue prevents the calculation of traditional growth rates, implying that the company is not yet generating commercial scale to measure expansion velocity. Consequently, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available cash and retained earnings are directed back into the business to fund research, development, and clinical trials rather than being distributed to shareholders. This reinvestment strategy is characteristic of clinical-stage biopharmaceutical companies that prioritize long-term asset building and platform expansion over immediate income distribution to investors. The overall growth and income profile is defined by a complete reliance on external capital markets and internal cash reserves to fuel expansion, with no current income generation or dividend yield available to provide returns to equity holders.